Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit

J Surg Oncol. 2020 Sep;122(3):570-571. doi: 10.1002/jso.25969. Epub 2020 Jun 10.

Authors

Giuseppe Lamberti¹, Lisa Manuzzi¹, Ilaria Maggio¹, Davide Campana²

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy.
² Department of Medical and Surgical Sciences, S.Orsola-Malpighi University Hospital, Bologna, Italy.

PMID: 32519754
DOI: 10.1002/jso.25969

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Intestinal Neoplasms*
Neuroendocrine Tumors*
Pancreatic Neoplasms*
Stomach Neoplasms*